Physician profile
Kuljit Singh
NPI 1548236854
$8,135.69
in general payments reported to CMS, 2019-2025
20 companies · $1,965 in 2025
The $1,965 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $731 · 2021: $1,113 · 2022: $879 · 2023: $1,171 · 2024: $1,777 · 2025: $1,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,886 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,886.19 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,644.89 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $1,613.82 | 2023-2025 | Auvelity |
| Alkermes, INC. | $1,174.29 | 2019-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $970.38 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $954.97 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $407.16 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $333.93 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $311.83 | 2023-2025 | Caplyta |
| Corium, LLC | $169.65 | 2022-2024 | Azstarys |
| Allergan, INC. | $125.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $94.24 | 2024-2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $65.68 | 2025 | Fanapt |
| Almatica Pharma LLC | $61.31 | 2024 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $54.06 | 2025 | Qelbree |
| Bioxcel Therapeutics, INC. | $48.34 | 2023 | Igalmi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.08 | 2025 | Rejoyn |
| Orexo US, INC. | $22.53 | 2024 | Zubsolv |
| Collegium Pharmaceutical, INC. | $21.50 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $19.84 | 2021 | |
| Lundbeck LLC | $18.19 | 2025 | Abilify Maintena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kuljit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.